Reset filter
Nyckelord
Parkinsons Disease ×
Visa mer Nyckelord
Innehållsförteckning
  1. 1. Klinisk studie
    1. 1.1. Inkluderande/exkluderande
    1. 1.2. Anamnes
    1. 1.3. Kroppsundersökning
    1. 1.4. Poäng
    1. 1.5. Apparativ diagnostik
    1. 1.6. Laboratorium
    1. 1.7. Patologi och histologi
    1. 1.8. Upplysning/samtycke
    1. 1.9. Terapi
    1. 1.10. Operationsberättelse
    1. 1.11. Oönskad händelse
    1. 1.12. Uppföljning
  2. 2. Rutindokumentation
  3. 3. Register- och kohortstudier
  4. 4. Kvalitetssäkring
  5. 5. Datastandard
  6. 6. Frågeformulär för patienter
  7. 7. Medicinsk specialitet
Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

301 Sökresultat.
Relevans Bedömning Nya först Gamla först

Study Conclusion End of Study Ropinirole NCT00632736 - Study Conclusion End of Study

- 2017-07-30 - 1 Formulär, 2 Item-grupper, 6 Dataelement, 1 Språk
Item-grupper: STUDY CONCLUSION, Pregnancy information
Study part: Study Conclusion End of Study.An Open-Label Extension phase 3 Study with REQUIP (ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169 Patient Level Data. Study ID:101468/248, Clinical Study ID: 101468/248.

Study conclusion GSK study Dyskinesia in Parkinson's disease NCT00363727

- 2017-09-08 - 1 Formulär, 5 Item-grupper, 13 Dataelement, 1 Språk
Item-grupper: General information, Pregnancy information, Study conclusion, Investigator comment log, Investigator signature
Study ID: 101468/228 Clinical Study ID: 101468/228 Study Title:A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363727 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Dyskinesias; Parkinson Disease; Parkinson's Disease Study part: Study conclusion.

Pre-study PD medications GSK study Dyskinesia in Parkinson's disease NCT00363727

- 2017-09-07 - 1 Formulär, 3 Item-grupper, 21 Dataelement, 1 Språk
Item-grupper: General information, Prior L-Dopa medication, Prior Parkinson's medication
Study ID: 101468/228 Clinical Study ID: 101468/228 Study Title:A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363727 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Dyskinesias; Parkinson Disease; Parkinson's Disease Study part: Pre-study PD medications

Study Conclusion Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole NCT00460148

- 2017-03-13 - 1 Formulär, 1 Item-grupp, 4 Dataelement, 1 Språk
Item-grupp: Study Conclusion
Documentation Part: Study Conclusion An Open Label, Repeat Dose, Dose Escalation Study Conducted in Parkinson's Disease Patients to Characterize the Pharmacokinetics and Effect of Food on Ropinirole Prolonged Release (PR/CR) 12mg Tablets. ClinicalTrials.gov Identifier: NCT00460148 https://clinicaltrials.gov/ct2/show/NCT00460148?term=NCT00460148&rank=1 Responsible Party: GlaxoSmithKline

Investigator’s Signature End of Study Ropinirole NCT00632736 - Investigator’s Signature End of Study

- 2017-07-30 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Investigators signature
Study part: Investigator’s Signature End of Study.An Open-Label Extension phase 3 Study with REQUIP (ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169 Patient Level Data. Study ID:101468/248, Clinical Study ID: 101468/248.

Study Conclusion Early Withdrawal Ropinirole NCT00632736 - Study Conclusion Early Withdrawal

- 2017-07-30 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Study conclusion
Study part: Study Conclusion Early Withdrawal.An Open-Label Extension phase 3 Study with REQUIP (ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169 Patient Level Data. Study ID:101468/248, Clinical Study ID: 101468/248.

Study Conclusion Week 52 Ropinirole NCT00632736 - Study Conclusion Week 52

- 2017-07-30 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Study conclusion
Study part: Study Conclusion Week 52.An Open-Label Extension phase 3 Study with REQUIP (ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169 Patient Level Data. Study ID:101468/248, Clinical Study ID: 101468/248.

Demography GSK study Dyskinesia in Parkinson's disease NCT00363727

- 2021-09-20 - 1 Formulär, 2 Item-grupper, 7 Dataelement, 1 Språk
Item-grupper: General information, Demography
Study ID: 101468/228 Clinical Study ID: 101468/228 Study Title:A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363727 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Dyskinesias; Parkinson Disease; Parkinson's Disease Study part: Demography.

Dyskinesias GSK study Dyskinesia in Parkinson's disease NCT00363727

- 2017-09-08 - 1 Formulär, 2 Item-grupper, 7 Dataelement, 1 Språk
Item-grupper: General information, Dyskinesia
Study ID: 101468/228 Clinical Study ID: 101468/228 Study Title:A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363727 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Dyskinesias; Parkinson Disease; Parkinson's Disease Study part: Dyskinesias.

MMSE GSK study Dyskinesia in Parkinson's disease NCT00363727

- 2017-09-07 - 1 Formulär, 2 Item-grupper, 2 Dataelement, 1 Språk
Item-grupper: General information, Mini-Mental State Examination
Study ID: 101468/228 Clinical Study ID: 101468/228 Study Title:A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363727 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Dyskinesias; Parkinson Disease; Parkinson's Disease Study part: MMSE.

Investigator Comment Log End of Study Ropinirole NCT00632736 - Investigator Comment Log End of Study

- 2017-07-30 - 1 Formulär, 1 Item-grupp, 3 Dataelement, 1 Språk
Item-grupp: Investigator comment log
Study part: Investigator Comment Log End of Study.An Open-Label Extension phase 3 Study with REQUIP (ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169 Patient Level Data. Study ID:101468/248, Clinical Study ID: 101468/248.

study conclusion Ropinirole CR Ropinirole IR Monotherapy 101468/168

- 2017-10-18 - 1 Formulär, 5 Item-grupper, 10 Dataelement, 1 Språk
Item-grupper: administrative data, Study conclusion, Pregnancy information, Overall compliance, Investigator signature
Study ID: 101468/168 Clinical Study ID: 101468/168 Study Title: A Randomised, Double Blind, Three Period, Cross-Over Study of Ropinirole CR and Ropinirole IR Monotherapy Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara Study Indication: Parkinson Disease

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial